Legend Capital, a VC&PE investor focusing on the early-stage and growth-stage opportunities in China, led a $224m Series C round in Probio Technology, a health care technology solutions provider, with participation from Highlight Capital, Hillhouse, and other institutional investors. ProBio offers end-to-end contract development and manufacturing organization services from drug discovery to commercialization for antibodies, cell and gene therapies. The company said it would use the capital to increase manufacturing capacity, advance its R&D offerings and acquire companies that add services.